Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 emactuzumab versus placebo in tenosynovial giant cell tumour
NL-OMON59608Phase 3Active, not recruiting
- Sponsor
- SynOx Therapeutics
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) comparing Emactuzumab with Placebo (2 arms). Primary endpoint: Objective response rate by RECIST v1.1 at 6 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
emactuzumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON59608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59608.